BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li HT, Lu YY, An YX, Wang X, Zhao QC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep. 2011;25:1691-1697. [PMID: 21424126 DOI: 10.3892/or.2011.1217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 35] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo F, Gong H, Zhao H, Chen J, Zhang Y, Zhang L, Shi X, Zhang A, Jin H, Zhang J, He Y. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Sci Rep 2018;8:6076. [PMID: 29666387 DOI: 10.1038/s41598-018-24306-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
2 Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 2015;15:340. [PMID: 25929517 DOI: 10.1186/s12885-015-1345-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
3 Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q, Fu WL. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e90607. [PMID: 24594804 DOI: 10.1371/journal.pone.0090607] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 9.8] [Reference Citation Analysis]
4 Lu JW, Raghuram D, Fong PA, Gong Z. Inducible Intestine-Specific Expression of krasV12 Triggers Intestinal Tumorigenesis In Transgenic Zebrafish. Neoplasia 2018;20:1187-97. [PMID: 30390498 DOI: 10.1016/j.neo.2018.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
5 Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012;55:128-133. [PMID: 22228154 DOI: 10.1097/dcr.0b013e31823c08b3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
6 Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-54. [PMID: 22427238 DOI: 10.1136/gutjnl-2011-300865] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 10.0] [Reference Citation Analysis]
7 Sim J, Yi K, Kim H, Ahn H, Chung Y, Rehman A, Jang SM, Lee KH, Jang K, Paik SS. Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma. Gastroenterol Res Pract 2015;2015:283764. [PMID: 25688264 DOI: 10.1155/2015/283764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
8 Franczak C, Kandathil SM, Gilson P, Husson M, Rouyer M, Demange J, Leroux A, Merlin JL, Harlé A. Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing. Sci Rep 2019;9:7083. [PMID: 31068650 DOI: 10.1038/s41598-019-43646-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 2017;31:370-82. [PMID: 28289141 DOI: 10.1101/gad.293449.116] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 12.8] [Reference Citation Analysis]
10 Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One. 2012;7:e36653. [PMID: 22586484 DOI: 10.1371/journal.pone.0036653] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
11 Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clin Cancer Res. 2017;23:4919-4928. [PMID: 28446508 DOI: 10.1158/1078-0432.ccr-16-2656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 7.6] [Reference Citation Analysis]
12 Hugen N, Simons M, Halilović A, van der Post RS, Bogers AJ, Marijnissen-van Zanten MA, de Wilt JH, Nagtegaal ID. The molecular background of mucinous carcinoma beyond MUC2. J Pathol Clin Res 2015;1:3-17. [PMID: 27499889 DOI: 10.1002/cjp2.1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
13 Park SM, Jeon SK, Kim OH, Ahn JY, Kim CH, Park SD, Lee JH. Anti-tumor effects of the ethanolic extract of Trichosanthes kirilowii seeds in colorectal cancer. Chin Med 2019;14:43. [PMID: 31624493 DOI: 10.1186/s13020-019-0263-8] [Reference Citation Analysis]
14 Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. J Cancer. 2013;4:320-322. [PMID: 23569465 DOI: 10.7150/jca.3619] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
15 Zhang X, Wu J, Wang L, Zhao H, Li H, Duan Y, Li Y, Xu P, Ran W, Xing X. HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China. PeerJ 2020;8:e8602. [PMID: 32095377 DOI: 10.7717/peerj.8602] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol 2014;31:124. [PMID: 25073438 DOI: 10.1007/s12032-014-0124-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
17 Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer 2014;13:168. [PMID: 25005754 DOI: 10.1186/1476-4598-13-168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
18 Wang J, Shen J, Huang C, Cao M, Shen L. Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis. J Cancer. 2019;10:2332-2341. [PMID: 31258736 DOI: 10.7150/jca.30789] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
19 Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 2013;8:e81628. [PMID: 24339949 DOI: 10.1371/journal.pone.0081628] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
20 Luo Q, Chen D, Fan X, Fu X, Ma T, Chen D. KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report. Transl Oncol 2020;13:100874. [PMID: 32947236 DOI: 10.1016/j.tranon.2020.100874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
21 Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer. 2014;14:802. [PMID: 25367198 DOI: 10.1186/1471-2407-14-802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
22 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
23 Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol 2015; 21(5): 1595-1605 [PMID: 25663779 DOI: 10.3748/wjg.v21.i5.1595] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
24 Liu J, Tang L, Yi J, Li G, Lu Y, Xu Y, Zhao S, Mao R, Li X, Ren L, Wang K. Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer. BMC Gastroenterol 2019;19:173. [PMID: 31690257 DOI: 10.1186/s12876-019-1086-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Reggiani Bonetti L, Barresi V, Maiorana A, Manfredini S, Caprera C, Bettelli S. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer. Dis Markers. 2018;2018:2959801. [PMID: 30018674 DOI: 10.1155/2018/2959801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
26 Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 2014;5:11752-77. [PMID: 25361007 DOI: 10.18632/oncotarget.2555] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
27 Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, Miron L, Rusu C. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol 2019;53:265-74. [PMID: 31553708 DOI: 10.2478/raon-2019-0033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
28 Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis. 2013;28:1637-1642. [PMID: 23728594 DOI: 10.1007/s00384-013-1715-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
29 Miree O, Srivastava SK, Dasgupta S, Singh S, Rocconi R, Singh AP. Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. Adv Exp Med Biol 2021;1330:1-19. [PMID: 34339027 DOI: 10.1007/978-3-030-73359-9_1] [Reference Citation Analysis]
30 Yang Q, Huo S, Sui Y, Du Z, Zhao H, Liu Y, Li W, Wan X, Liu T, Zhang G. Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers. Front Oncol 2018;8:487. [PMID: 30416987 DOI: 10.3389/fonc.2018.00487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
31 Saldanha SN, Tollefsbol TO. Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol 2014;229:393-406. [PMID: 24105793 DOI: 10.1002/jcp.24466] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
32 Zhang X, Ran W, Wu J, Li H, Liu H, Wang L, Xiao Y, Wang X, Li Y, Xing X. Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China. PeerJ 2018;6:e4341. [PMID: 29423347 DOI: 10.7717/peerj.4341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 2014;5:8937-46. [PMID: 25313136 DOI: 10.18632/oncotarget.2339] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Nguyen HT, Le DT, Duong QH, Tatipamula VB, Van Nguyen B. High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer. Oncol Lett 2021;21:41. [PMID: 33262833 DOI: 10.3892/ol.2020.12302] [Reference Citation Analysis]
35 Cheng HH, Lin JK, Chen WS, Jiang JK, Yang SH, Chang SC. Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Int J Colorectal Dis. 2018;33:1173-1181. [PMID: 29869121 DOI: 10.1007/s00384-018-3095-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]